All News

liveVote2.jpg

X-Linked Hypophophatemia - Survey Results

d Jack Cush, MD

The July 2021 RheumNow “Live Vote” surveyed US and non-US rheumatologists on their knowledge and practices when dealing with the bone disorder, X-linked hypophosphatemia (XLH).

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
pediatric.kid_.jpg

Pediatric Rheumatology Workforce Shortages

d Jack Cush, MD

Two recent analyses from the USA and Canada point to a significant unmet need with regard to pediatric rheumatologists.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

ACR/EULAR 2022 Classification Criteria for EGPA

d Jack Cush, MD

The 2022 ACR/EULAR revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA) have been revised and validated for use in clinical research.

Read Article
ANCA, vasculitis, test

ACR/EULAR 2022 Classification Criteria for Granulomatosis with Polyangiitis

d Jack Cush, MD

The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.

Read Article
ANCA, vasculitis, test

ACR/EULAR 2022 Classification Criteria for Microscopic Polyangiitis

d Jack Cush, MD

The 2022 ACR/EULAR  classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.

Read Article
gout.podagra_0.jpg

Healthy Diets Prevent Gout in Women

d Jack Cush, MD

A prospective cohort from the Nurses’ Health Study has demonstrated that eating a healthy diet results in a 12% to 32% lower risk of incident gout and an even greater risk reduction (65% to 68%) when combined with normal weight and avoiding diuretics.

Read Article
Retrospective study of 84 pts with Erosive Hand OsteoArthritis (EHOA)- 89% females DIPs erosions scores were higher than PIP’s. Comorbid dz = crystal arthritis (8%), RA (5%) & PsA (1%), Pain usually >5/10 w/ 1/3 responding to NSAIDs. Big Unmet need! https://t.co/jQ3yNgaZBA

Links:

Dr. John Cush RheumNow ( View Tweet)

Treatment of Complex regional pain syndrome type-I (CRPS-I) in adults is difficult! A Systematic review shows that only parenteral bisphosphonates (and maybe ketamine) lowered VAS/NRS pain scales vs placebo. https://t.co/m4SpO4P96J

Links:

Dr. John Cush RheumNow ( View Tweet)

Persons living with diagnosed HIV (PLWDH) have more hospitalizations and death from COVID-19 than those not HIV+. In 100K PLWDH, 63%) were fully vaccinated, 4% partly Vax & 32% no Vax. VAX in PLWDH was lower than gen population (63% vs 75%) https://t.co/oegf5WjmNF

Links:

Dr. John Cush RheumNow ( View Tweet)

In the USA, the prevalence of Vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020). Approximately 40% of adult vitiligo in the US may be undiagnosed. https://t.co/rsyoIbHmS8

Links:

Dr. John Cush RheumNow ( View Tweet)

Radiographic progression in AxSpA studied in 101 Spanish Pts - pts w/ sustained low ASDAS had less XRay progression than those with active Dz (2.33 vs 1.76, p=0.027). Long term TNFi use didnt influence progression until the 3rd Yr https://t.co/KHCdzbqhzr

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has expanded its approval of REMDESIVIR for use in non-hospitalizedadults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. Previously, Veklury was limited to hospitalized COVID-19 pts. https://t.co/dHbomchfB5

Links:

Dr. John Cush RheumNow ( View Tweet)

Interested in our most popular articles? Head over to RheumNow. https://t.co/8JLpph3or8

Links:

Dr. John Cush RheumNow ( View Tweet)

Finnish Parkinson’s disease (FINPARK) cohort (22,189) looked at the assoc w/ #RA. RA pts using only chloroquine/hydroxychloroquine was associated with a lower risk of developing PD (adjusted OR 0.74); not with other DMARDs https://t.co/yZhgVT0xLh

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg

Links:

Dr. John Cush RheumNow ( View Tweet)

Top Tweet in January Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/j0BRs9snVH https://t.co/4OTmbNJ2GP

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live: Shorter Lectures, More Discussion - Rheumatologists like us, go to meetings like this; meetings that matter; meetings that change thinking We have a packed agenda with experts from around the world. https://t.co/94QmsCqSdj https://t.co/DIJrI8hwDa

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of Academic Clinicians showed that for every $1 generated though office visits (E&M coding) by 5 practicing academic rheums, $12.14 were generated through downstream revenue (mostly infusions). https://t.co/YQ1RL5JF9u

Links:

Dr. John Cush RheumNow ( View Tweet)

The US FDA has published a 52 page report entitled, "DRUG SAFETY PRIORITIES 2021" covering, REMS, Sentinal program, Drug safety communications (eg, Xeljanz), nitrosamine impurities (NMDA), opioids, COVID drug safety & more...https://t.co/vcMZqkdsz5

Links:

Dr. John Cush RheumNow ( View Tweet)

×